简体中文| English
HomeNEWS AND MEDIA

On Feb 5, 2021, MRG004A received IND clearance for Phase I/II clinical study from the US FDA.

Release time：2021-02-05

Shanghai Miracogen Inc.

ADDRESS：No. 1238 Zhangjiang Rd, Building 3, Suite 4E, Pudong District, Shanghai, 201203, China

TEL：86-21-61637960

EMAIL：Info@miracogen.com.cn

ABOUT US :
Copyright 2017 Shanghai Miracogen Inc.沪ICP备17030155号